Florida Cancer Specialists & Research Institute Announces Addition to Executive Management Team

FORT MYERS, Fla., Sept. 10, 2025 /PRNewswire/ -- Florida Cancer Specialists & Research Institute, LLC (FCS) has announced the promotion of Jacqueline Ambrose to the position of FCS General Counsel.

As FCS' General Counsel, Ambrose is responsible for leading the legal strategy of the oncology practice and providing counsel on regulatory compliance, risk management, and corporate governance. She provides strategic oversight for FCS' approach to dispute resolution, complex litigation, and medical malpractice matters.

"We are thrilled to welcome Jacqueline into the role of General Counsel. She brings exceptional legal expertise and a deep understanding of our organization's mission and values," said FCS President & Managing Physician, Lucio N. Gordan, MD.

Jacqueline joined FCS in 2021 and served as FCS Associate General Counsel, advising on various legal matters, including supporting clinical operations, privacy, and human resources. She also advised Executive Leadership on litigation strategy and oversaw outside counsel.

"Jacqueline's collaborative approach, strategic insight, and passion for patient advocacy have earned her recognition as a trusted advisor across departments and among senior leadership," said FCS Assistant Managing Physician David Wenk, MD.

FCS Chief Executive Officer Ryan Ciarrocchi added, "I am confident in Jacqueline – she is well-positioned in her new role to provide exceptional leadership and guidance as we continue to grow and navigate new opportunities for our practice and ultimately our patients."

About Florida Cancer Specialists & Research Institute, LLC: (FLCancer.com)
For more than 40 years, Florida Cancer Specialists & Research Institute (FCS) has embraced innovation to deliver world-class care and drive the dramatic transformation of oncology care through its robust clinical research program.

FCS provides patients with access to a wide range of clinical trials, positioning it as a leader in research among private oncology practices in Florida and across the country. In fact, before receiving FDA approval, the majority of new cancer drugs in the U.S. were first made available to patients through participation in clinical trials at FCS.

Our outstanding team of highly trained and dedicated physicians is committed to delivering tailored treatment plans that best use cutting-edge precision oncology advancements to enhance patient outcomes.

SOURCE Florida Cancer Specialists & Research Institute